chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. aiming to be a healthcare group with a global presence, fosun pharma, established in shanghai in 1994, has built its core business around innovative drug r&d and manufacturing.
innovation for health — the fourth hongqiao international health technology innovation forum held in shanghai
on november 6, 2021, as a parallel supporting event of the 4th china international import expo (ciie), the 4th hongqiao international health technology innovation forum with the theme of "innovation for good health" was successfully held. this forum was sponsored by the international health exchange and cooperation center nhc prc (ihecc) and china pharmaceutical innovation and research development association,
2021 csco | henlius publishes newest phase ii clinical data of novel anti-pd-1 mab serplulimab for treatment of advanced cervical cancer
in this meeting, henlius releases phase 2 study results of serplulimab (hlx10, novel anti-pd-1 antibody), in patients with advanced cervical cancer in an oral presentation.
2021 csco | henlius publishes phase iii clinical data of bevacizumab biosimilar hlx04 for treatment of metastatic colorectal cancer
in this meeting, henlius releases phase 3 study results of hlx04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
brief product news | new progress in henlius anti-her2 therapy! first patient dosed in phase 1 clinical trial of henlius pertuzumab biosimilar hlx11
hlx11 was independently developed by henlius with the pertuzumab originator as reference drug and the development is in accordance with china's biosimilar guidelines.
henlius bevacizumab biosimilar hlx04 receives nda acceptance notification from nmpa
hlx04 was developed with the bevacizumab originator as reference product and the development process is in line with china’s biosimilar guidelines.